Sunday, May 09, 2021 9:22:15 AM
In a 263-page document, written by People’s Liberation Army scientists and senior Chinese public health officials and obtained by the US State Department during its investigation into the origins of COVID-19, PLA scientists note how a sudden surge of patients requiring hospitalization during a bioweapon attack “could cause the enemy’s medical system to collapse,” according to The Weekend Australian (a subsidiary of News Corp).
It suggests that SARS coronaviruses could herald a “new era of genetic weapons,” and noted that they can be “artificially manipulated into an emerging human disease virus, then weaponized and unleashed in a way never seen before.”
And as we noted in March, the US National Institutes of Health (NIH) – headed by Dr. Anthony Fauci, “had funded a number of projects that involved WIV scientists, including much of the Wuhan lab’s work with bat coronaviruses.”
In 2017, Fauci’s agency resumed funding a controversial grant to genetically modify bat coronaviruses in Wuhan, China without the approval of a government oversight body, according to the Daily Caller. For context, in 2014, the Obama administration temporarily suspended federal funding for gain-of-function research on bat coronaviruses. Four months prior to that decision, the NIH effectively shifted this research to the Wuhan Institute of Virology (WIV) via a grant to nonprofit group EcoHealth Alliance, headed by Peter Daszak.
The NIH’s first $666,442 installment of EcoHealth’s $3.7 million grant was paid in June 2014, with similar annual payments through May 2019 under the “Understanding The Risk Of Bat Coronavirus Emergence” project.
Notably, the WIV “had openly participated in gain-of-function research in partnership with U.S. universities and institutions” for years under the leadership of Dr. Shi ‘Batwoman’ Zhengli.
Recent PFE News
- CVS Health, Starbucks, Shares Weaker; Pinterest Soars • IH Market News • 05/01/2024 01:12:05 PM
- Pfizer Reports First-Quarter 2024 Results • Business Wire • 05/01/2024 10:45:00 AM
- TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer • Business Wire • 04/29/2024 10:40:00 PM
- FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer • Business Wire • 04/29/2024 10:40:00 PM
- Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting • Business Wire • 04/29/2024 10:45:00 AM
- Anglo American Rejects BHP Group’s Offer, Toyota Invests $1.4 Billion in Indiana, and More News • IH Market News • 04/26/2024 11:48:07 AM
- U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B • Business Wire • 04/26/2024 10:45:00 AM
- Pfizer Declares Second-Quarter 2024 Dividend • Business Wire • 04/24/2024 08:37:00 PM
- Coca-Cola and Microsoft Sign Billion-Dollar Agreement, Apple Event Set for May 7, and More News • IH Market News • 04/24/2024 11:28:02 AM
- European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options • Business Wire • 04/22/2024 12:08:00 PM
- Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25 • Business Wire • 04/11/2024 02:00:00 PM
- Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News • IH Market News • 04/10/2024 11:13:48 AM
- Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease • Business Wire • 04/09/2024 10:45:00 AM
- ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager • PR Newswire (US) • 04/08/2024 04:44:00 PM
- Super Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest News • IH Market News • 03/26/2024 11:20:49 AM
- Apple Pre-Market Drop Due to Antitrust Threats, Surprising Profit Boosts Micron Shares, and Latest Market Updates • IH Market News • 03/21/2024 11:17:26 AM
- Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts • Business Wire • 03/20/2024 02:00:00 PM
- Unilever Initiates Ice Cream Division Spin-Off and Announces Job Cuts; Berkshire Ramps Up Share Buyback Efforts, and More • IH Market News • 03/19/2024 11:33:10 AM
- Apple & Google in Talks for Gemini AI on iPhone, Nvidia’s GTC Conference Today, and Latest News • IH Market News • 03/18/2024 11:10:46 AM
- European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease • Business Wire • 03/13/2024 08:00:00 AM
- Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) • Business Wire • 03/12/2024 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 08:55:44 PM
- Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference • Business Wire • 03/05/2024 03:00:00 PM
- Futures Pointing To Continued Weakness On Wall Street • IH Market News • 03/05/2024 02:03:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 06:28:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM